ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Novel Bioresorbable Bone Wax for Potentiated Hemostasis and Osteogenesis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Efficacy and safety of a novel absorbable bone wax as a hemostatic agent for periacetabular osteotomy: a prospective, randomized controlled trial.BMC musculoskeletal disorders · 2026Trial
- Multifunctional Intelligent Hydrogels Based on MnOGels (Basel, Switzerland) · 2026Article
- Clinical Applications and Emerging Roles of Bone Wax in Orthopaedic Surgery: A Scoping Review.Journal of clinical medicine · 2026Review
- All-natural medicine food homology herb-based self-gelling hemostatic powder for rapid hemostasis and diabetic wound management.Journal of nanobiotechnology · 2026Article
- Novel Bioresorbable Bone Wax for Potentiated Hemostasis and Osteogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Orthopedic surgery faces dual challenges of uncontrolled bleeding and poor bone regeneration at defect sites. While traditional beeswax-based hemostats remain clinically prevalent, their non-resorbability impedes healing and triggers chronic inflammation. This study introduces a "hemostasis-resorption-osteogenesis" synergistic design paradigm, developing a novel bioresorbable bone wax based on a polymer dispersion matrix that integrates a quaternized cationic starch (QS) and β-tricalcium phosphate (β-TCP) dual-phase promoting matrix (PST). PST bone wax's physicochemical properties, characterized via finger pressing models and in vitro sealing assays, demonstrate excellent plasticity and adhesiveness, enabling rapid sealing and prolonged hemostasis under physiological blood pressure. It gradually resorbs, releasing Ca
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.